Gilead Sciences (GILD) Total Non-Current Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Non-Current Liabilities for 18 consecutive years, with $36.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities rose 3.45% year-over-year to $36.0 billion; the trailing twelve-month figure through Jun 2026 stood at $36.0 billion (up 3.45% YoY), and the FY2025 full-year result was $35.2 billion, down 8.58% from the prior year.
• Total Non-Current Liabilities advanced to $36.0 billion in Q2 2026 per GILD's latest filing, from $31.6 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $38.8 billion in Q2 2022 and bottomed at $31.6 billion in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $36.5 billion across 5 years, with a median of $37.0 billion in 2023.
• The widest YoY moves for Total Non-Current Liabilities: up 3.45% in 2026, down 12.14% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $38.0 billion in 2022, then fell by 1.86% to $37.3 billion in 2023, then advanced by 2.99% to $38.5 billion in 2024, then fell by 8.58% to $35.2 billion in 2025, then grew by 2.53% to $36.0 billion in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $36.0 billion, $31.6 billion, and $35.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.